OESOPHAGEAL CARCINOMA THERAPY Russian patent published in 2009 - IPC A61N5/10 A61K35/14 A61K35/16 A61K31/513 A61K31/196 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in oesophageal carcinoma therapy. Substance of the invention consist that prior to radiation therapy, autoblood 400 ml is sampled. Plasma is separated by centrifugation. The first bottle is filled with autoplasma 40 ml and 5-fluorouracil 500 mg, while the second and third bottles are filled with autoplasma 40 ml, and the fourth with residual blood corpuscles and methotrexate 20 mg. The second and third bottles are frozen, and the first and fourth bottles are separately incubated for 40 minutes at 37°C. Then mixed autoblood and methotrexate from the fourth bottle are reinfused droplet-intravenously, mixed autoplasma and 5-fluorouracil from the first bottle are introduced into oesophagus through nasoesophageal probe and followed with the first session of radiation therapy. Intraesophageal autoplasma chemotherapy is carried out one day after the autoplasma bottle is unfrozen, added with 5-fluorouracil 500 mg and incubated in a thermostat. The entire therapy cycle is carried out for the following weeks of radiation therapy; irradiation is involved to TBD (total basic dose) 40-60 Gy at a single dose 2 Gy including 5 sessions a week.

EFFECT: method allows improving effectiveness of radiation therapy ensured by direct antineoplastic exposure of intraesophageal autoplasmochemotherapy and radiosensitisation of autohemochemotherapy.

1 ex